Compare Medpace Holdings Inc (MEDP) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Oatly Group AB - ADR — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Medpace Holdings Inc is far larger — about 50.8× Oatly Group AB - ADR's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Oatly Group AB - ADR for 18 Days on average.
| MEDP | OTLY | |
|---|---|---|
Market Cap | $16.82B | $330.93M |
Volume | 223,093 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $15.91 |
52-Week Low | $393.42 | $8.03 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $16.44B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
OTLY trades at $10.38 with minimal daily movement (+0.1%). The stock shows mixed signals with a bearish technical outlook but improving fundamentals. Recent Q2 2026 results showed revenue growth and margin improvement, though the company continues to post net losses. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The investment case hinges on Oatly's ongoing turnaround efforts showing progress through revenue growth and margin expansion. Key risks include persistent negative cash flow, high debt levels, and delayed profitability. The stock offers speculative appeal for investors betting on the plant-based beverage market growth and operational improvements, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
